The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
Open accessAbstract
BACKGROUND: Mineralocorticoid antagonists improve survival among patients with chronic, severe systolic heart failure and heart failure after myocardial infarction. We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms. METHODS: In this randomized, double-blind trial, we randomly assigned 2737 patients with New York Heart Association class II heart failure and an ejection fraction of no more than 35% to receive eplerenone (up to 50 mg daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. RESULTS: The trial was stopped prematurely, according to prespecified rules, after a median follow-up period of 21 months. The primary outcome occurred in 18.3% of patients in the eplerenone group as compared with 25.9% in the placebo group (hazard ratio, 0.63; 95% confidence interval [CI], 0.54 to 0.74; P<0.001). A total of 12.5% of patients receiving eplerenone and 15.5% of those receiving placebo died (hazard ratio, 0.76; 95% CI, 0.62 to 0.93; P=0.008); 10.8% and 13.5%, respectively, died of cardiovascular causes (hazard ratio, 0.76; 95% CI, 0.61 to 0.94; P=0.01). Hospitalizations for heart failure and for any cause were also reduced with eplerenone. A serum potassium level exceeding 5.5 mmol per liter occurred in 11.8% of patients in the eplerenone group and 7.2% of those in the placebo group (P<0.001). CONCLUSIONS: Eplerenone, as compared with placebo, reduced both the risk of death and the risk of hospitalization among patients with systolic heart failure and mild symptoms. (Funded by Pfizer; ClinicalTrials.gov number, NCT00232180.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This effect was independent of diabetes status, and baseline HbA1c did not modify the effects on the primary outcome.531”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [531]
In the citing paper
“The mortality benefit of spironolactone in the RALES trial and eplerenone in the EMPHASIS-HF trial was consistent in T2DM and non-T2DM patients with HFrEF.158,159”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [159]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationPitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Self-citationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
Dickstein, K., Authors Task Force Members, Solal, A. C., Filippatos, G. S., McMurray, J. J. V., Ponikowski, P. P., Poole-Wilson, P. A., Strömberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.005 · Cited by 3,535
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F. M., Remme, W. J., Cody, R. J., Castaigne, A., Pérez, A. J. P., Palensky, J., & Wittes, J. T. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Self-citationMcMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Self-citationIvabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563
Self-citationHunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M. L., Konstam, M. A., MANCINI, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,398
Zannad, F. M., Alla, F., Dousset, B., Pérez, A. J. P., & Pitt, B. (2000) · Circulation · doi:10.1161/01.cir.102.22.2700 · Cited by 946
Self-citationCalculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
McKelvie, R. S., Yusuf, S., Pericak, D., Avezum, A., Burns, R. J., Probstfield, J., Tsuyuki, R. T., White, M., Rouleau, J., Latini, R., et al. (1999) · Circulation · doi:10.1161/01.cir.100.10.1056 · Cited by 692
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,004
Sex Differences in Heart Failure
Savarese, G., & D’Amario, D. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77932-4_32 · Cited by 63
The Treatment of Heart Failure with Reduced Ejection Fraction
Berliner, D., Hänselmann, A., & Bauersachs, J. K. (2020) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2020.0376 · Cited by 62
Agarwal, R., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Ruilope, L. M., Boletis, J., Toto, R., Umpierrez, G. E., Wanner, C., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab336 · Cited by 61
Self-citationMineralocorticoid receptors in the heart: lessons from cell-selective transgenic animals
Young, M. J., & Rickard, A. J. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0471 · Cited by 61
“Large-scale clinical trials have subsequently validated the importance of MR signalling in cardiac pathology in patients with severe allcause heart failures (RALES), heart failure post myocardial infarction (EPHESUS) or mild heart failure (EMPHASIS-HF; Pitt et al. 1999, 2001, Zannad et al. 2011).”
BackgroundMcMurray, J. J. V., & O’Connor, C. M. (2014) · New England Journal of Medicine · doi:10.1056/nejme1401231 · Cited by 64
Self-citationAnuka, E., Gal, M., Stocco, D. M., & Orly, J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.02.003 · Cited by 60
Structural and molecular determinants of mineralocorticoid receptor signalling
Großmann, C., Almeida‐Prieto, B., Nolze, A., & de la Rosa, D. Á. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15746 · Cited by 64
“A significant improvement in cardiovascular outcome was also achieved in patients with mildly symptomatic left ventricular systolic dysfunction (EMPHASIS-HF) (Zannad et al., 2010).”
BackgroundMénard, J., Rigel, D. F., Watson, C. E., Jeng, A. Y., Fu, F., Beil, M. E., Liu, J., Chen, W., Hu, C.-W., Leung-Chu, J., et al. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0340-9 · Cited by 58
“aldosterone with mineralocorticoid receptor antagonists (MRAs) in the treatment of heart failure [3-5] provide the rationale for new therapeutic approaches to inhibit”
BackgroundHeart Failure: a Major Cardiovascular Complication of Diabetes Mellitus
Bahtiyar, G., Gutterman, D. D., & Lebovitz, H. E. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0809-4 · Cited by 60
Understanding acute heart failure: pathophysiology and diagnosis
Arrigo, M., Parissis, J., Akiyama, E., & Mebazaa, A. (2016) · European Heart Journal Supplements · doi:10.1093/eurheartj/suw044 · Cited by 71
The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure
Bayés‐Genís, A., Núñez, J. E., Zannad, F. M., Ferreira, J. P., Anker, S. D., Cleland, J. G. F., Dickstein, K., Filippatos, G. S., Lang, C. C., Ng, L. L., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.057 · Cited by 60
“València, Spain; CIBERCV; (3) Inserm, Centre d’Investigation Clinique Plurithématique 1433, Inserm U1116, Université de Lorraine, CHRU de Nancy, F-CRIN INICRCT, Nancy, France; (4) Department of Physiology and Cardiothoracic Surgery, Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto…”
BackgroundSelf-citationThe heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
Ofstad, A. P., Atar, D., Gullestad, L. L., Langslet, G., & Johansen, O. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9685-0 · Cited by 59
“1 a Incidence of HF hospitalization in the overall and DM subgroup in placebo/comparator-arms of HF trials of different interventions (ACEi [13, 17], digoxin [18, 19], β-blocker [20, 21], ARB [10, 22], If-blocker [23, 24], MRA [25, 26], and ARNI [27, 28]) and the relative incidence rate ratio for HF hospitalization fo…”
BackgroundInfluentialHein, A. M., Scialla, J. J., Edmonston, D. L., Cooper, L. B., DeVore, A. D., & Mentz, R. J. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.02.009 · Cited by 59
“Mineralocorticoid Receptor Antagonists In major RCTs, MRAs have consistently improved symptoms while reducing hospitalizations and mortality in patients with HFrEF.”
BackgroundInfluentialMineralocorticoid receptor in cardiovascular diseases—Clinical trials and mechanistic insights
Bauersachs, J. K., & López‐Andrés, N. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15708 · Cited by 57
“…in Mild Patients Hospita-lization And Survival Study in Heart Failure) expanded these findings, showing that eplerenone treatment in addition to standard therapy promoted a highly significant reduction in mortality and HF hospitalizations in patients with NYHA class II HFrEF (Zannad et al., 2011).”
Buysse, J., Huang, I., & Pitt, B. (2011) · Future Cardiology · doi:10.2217/fca.11.71 · Cited by 59
Self-citationGheorghiade, M., Vaduganathan, M., Greene, S. J., Mentz, R. J., Adams, K. F., Anker, S. D., Arnold, M., Baschiera, F., Cleland, J. G. F., Cotter, G., et al. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9361-8 · Cited by 57
“Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).”
InfluentialSelf-citationAbbas, S., Ihle, P., Harder, S., & Schübert, I. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3748 · Cited by 59
Tobe, S. W., Stone, J. A., Anderson, T. J., Bacon, S., CHENG, A. Y. Y., Daskalopoulou, S. S., Ezekowitz, J. A., Grégoire, J. C., Gubitz, G. J., Jain, R., et al. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.180194 · Cited by 62
Fish Oil and Post-Operative Atrial Fibrillation
Mozaffarian, D., Wu, J. H. Y., de Oliveira Otto, M. C., Sandesara, C. M., Metcalf, R. G., Latini, R., Libby, P., Lombardi, F., O'Gara, P. T., Page, R. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.045 · Cited by 57
Pitt, B., Bushinsky, D. A., Kitzman, D. W., Ruschitzka, F. T., Metra, M., Filippatos, G. S., Rossignol, P., Mond, C. D., Garza, D., Berman, L., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12265 · Cited by 58
Self-citationHeart Failure Clinical Trials in East and Southeast Asia
Mentz, R. J., Roessig, L., Greenberg, B., Sato, N., Shinagawa, K., Yeo, D., Kwok, B. W. K., Reyes, E. B., Krum, H., Pieske, B. M., et al. (2016) · JACC Heart Failure · doi:10.1016/j.jchf.2016.01.013 · Cited by 58
“6 , 2 0 1 6 Mentz et al. J U N E 2 0 1 6 : 4 1 9 – 2 7 Heart Failure in Asia 425 enrolled in Hong Kong, Korea, India, Singapore, and the United Arab Emirates (57).”
Self-citationPei, H., Wang, W., Zhao, D., Wang, L., Su, G., & Zhao, Z. (2018) · Medicine · doi:10.1097/md.0000000000010254 · Cited by 60
Schumacher, C., Steele, R. E., & Brunner, H. R. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328363570c · Cited by 56
Maggioni, A. P., Greene, S. J., Fonarow, G. C., Böhm, M., Zannad, F. M., Solomon, S. D., Lewis, E. F., Baschiera, F., Hua, T., Gimpelewicz, C. R., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht342 · Cited by 55
Self-citationNorberg, H., Bergdahl, E., & Lindmark, K. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12251 · Cited by 55
Pitt, B., Bakris, G. L., Weir, M. R., Freeman, M. W., Lainščak, M., Mayo, M. R., Garza, D., Zawadzki, R., Berman, L., & Bushinsky, D. A. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12292 · Cited by 55
Self-citationHeart Failure: A Class Review of Pharmacotherapy.
Shah, A. A., Gandhi, D., Srivastava, S., Shah, K. J., & Mansukhani, R. P. (2017) · PubMed Central · Cited by 55
Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure
Ferreira, J. P., Zannad, F. M., Butler, J., Filippatos, G. S., Pocock, S., Brueckmann, M., Steubl, D., Schueler, E., Anker, S. D., & Packer, M. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.2924 · Cited by 57
Self-citationRepresentativeness in randomised clinical trials supporting acute coronary syndrome guidelines
Mas-Lladó, C., González‐Del‐Hoyo, M., Siquier-Padilla, J., Peña, L. B., Coughlan, J. J., de la Villa, B. G., Peral, V., & Rosselló, X. (2023) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcad007 · Cited by 56
Adverse Effects of Aldosterone: Beyond Blood Pressure
Brown, J. M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.030142 · Cited by 61
“…a 24% (95% CI, 0.62–0.93) reduction in death and a 42% (95% CI, 0.47–0.70) reduction in HF hospitalization in patients with mild systolic HF 40 and a 15% (95% CI, 0.75–0.96) reduction in all-cause death and a 15% (0.74–0.99) reduction in HF hospitalization in patients with HF following…”
BackgroundInfluential2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 109
Digitalis for treatment of heart failure in patients in sinus rhythm
Hood Jr., W. B., Dans, A. L., Guyatt, G. H., Jaeschke, R., & McMurray, J. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002901.pub3 · Cited by 56
Self-citationButler, J., Ezekowitz, J. A., Collins, S. P., Givertz, M. M., Teerlink, J. R., Walsh, M. N., Albert, N. M., Canary, C. A. W., Carson, P. E., Colvin, M. M., et al. (2012) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2012.02.005 · Cited by 58
Nehme, A., & Zibara, K. (2017) · Hypertension Research · doi:10.1038/hr.2017.65 · Cited by 58
Neefs, J., van den Berg, N. W. E., Krul, S. P. J., Boekholdt, S. M., & de Groot, J. R. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00353-5 · Cited by 56
Rosselló, X., Ferreira, J. P., Pocock, S., McMurray, J. J. V., Solomon, S. D., Lam, C. S. P., Girerd, N., Pitt, B., Rossignol, P., & Zannad, F. M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1740 · Cited by 55
Self-citationKario, K., Hoshide, S., Narita, K., Okawara, Y., Kanegae, H., Aoki, K., Kihara, H., Koga, T., Nakata, T., Oku, K., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.18198 · Cited by 55
Aimo, A., Vergaro, G., González, A., Barison, A., Lupón, J., Delgado, V., Richards, M., de Boer, R. A., Thum, T., Arfsten, H., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2522 · Cited by 55
Maheshwari, A., Norby, F. L., Inciardi, R. M., Wang, W., Zhang, M. J., Soliman, E. Z., Alonso, Á., Johansen, M. C., Gottesman, R. F., Solomon, S. D., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-1638 · Cited by 55
Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials
Oraii, A., Healey, J. S., Kowalik, K., Pandey, A. K., Benz, A. P., Wong, J. A., Conen, D., & McIntyre, W. F. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad811 · Cited by 57
Interactions of the mineralocorticoid receptor – Within and without
Yang, J., & Fuller, P. J. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.001 · Cited by 59
Semiparametric regression for the weighted composite endpoint of recurrent and terminal events
Mao, L., & Lin, D. Y. (2015) · Biostatistics · doi:10.1093/biostatistics/kxv050 · Cited by 55
Biomarkers: optimizing treatment guidance in heart failure
Böhm, M., Voors, A. A., Ketelslegers, J., Schirmer, S. H., Turgonyi, E., Bramlage, P., & Zannad, F. M. (2011) · Clinical Research in Cardiology · doi:10.1007/s00392-011-0341-0 · Cited by 54
Self-citationPascual-Figal, D. A., Wachter, R., Senni, M., Bělohlávek, J., Noè, A., Carr, D., & Butylin, D. (2017) · ESC Heart Failure · doi:10.1002/ehf2.12246 · Cited by 54
Aldosterone receptor antagonists: current perspectives and therapies
Clark, D., Guichard, J. L., Calhoun, & Ahmed (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33759 · Cited by 57
Lother, A., Fürst, D., Bergemann, S., Gilsbach, R., Grahammer, F., Huber, T. B., Hilgendorf, I., Bode, C., Moser, M., & Hein, L. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.06530 · Cited by 55
“The usage of mineralocorticoid receptor antagonists (MRAs) has proven highly beneficial during cardiac disease.(13,14) In animal models of hypertensive nephropathy, the MRA spironolactone reduced renal injury independently from blood pressure.”
BackgroundFerreira, J. P., Girerd, N., Medeiros, P. B., Santos, M., Carvalho, H. C., Bettencourt, P., Kénizou, D., Butler, J., Zannad, F. M., & Rossignol, P. (2015) · Clinical Research in Cardiology · doi:10.1007/s00392-015-0945-x · Cited by 54
Self-citationChang, H., Wang, C., Wei, J., Chang, C.-Y., Chuang, Y.-C., Huang, C.-L., Chong, E. Y., Lin, J.-L., Mar, G.-Y., Chan, K., et al. (2017) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2017.04.011 · Cited by 54
CSI position statement on management of heart failure in India
Guha, S., Harikrishnan, S., Ray, S., Sethi, R., Ramakrishnan, S., Banerjee, S., Bahl, V. K., Goswami, K. C., Banerjee, A. K., Shanmugasundaram, S., et al. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.05.003 · Cited by 59
Lachaux, M., Barrera‐Chimal, J., Nicol, L., Rémy‐Jouet, I., Renet, S., Dumesnil, A., Wecker, D., Richard, V. J., Kolkhof, P., Jaisser, F., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13393 · Cited by 54
Atherton, J. J., Sindone, A. P., Pasquale, C. G. D., Driscoll, A. L., Macdonald, P. S., Hopper, I., Kistler, P. M., Briffa, T. G., Wong, J., Abhayaratna, W. P., et al. (2018) · The Medical Journal of Australia · doi:10.5694/mja18.00647 · Cited by 55
Taylor, R. S., Sadler, S., Dalal, H. M., Warren, F. C., Jolly, K. B., Davis, R., Doherty, P., Miles, J., Greaves, C. J., Wingham, J., et al. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319833507 · Cited by 57
Lumbers, R. T., Martin, N., Manoharan, K., Nyong, J., Thomas, J., Casas, J. P., & Davies, C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012721 · Cited by 56
Hu, J., Shen, H., Huo, P., Yang, J., Fuller, P. J., Wang, K., Yang, Y., Ma, L., Cheng, Q., Gong, L., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.023082 · Cited by 53
Kintscher, U., & Edelmann, F. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01899-0 · Cited by 58
“737 patients with LV-EF ≤ 30% and NYHA stage II, eplerenone treatment induced a significant decline of all-cause and CV death, and hospitalization rate in the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS) [5, 25].”
BackgroundInfluentialCardiovascular Disease in the Elderly
Jackson, C. F., & WENGER, N. K. (2011) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.05.003 · Cited by 55
Morales, E., Millet, V. G., Rojas-Rivera, J. E., Huerta, A., Gutiérrez, E., Gutiérrez-Solís, E., Egido, J., & Praga, M. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs429 · Cited by 55
Improving outcomes in heart failure: a personal perspective
McMurray, J. J. V. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv565 · Cited by 53
Self-citationDeFronzo, R. A., CHILTON, R. J., Norton, L., Clarke, G., Ryder, R. E. J., & Abdul‐Ghani, M. A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12652 · Cited by 53
“With regard to the latter, the reduction in hospitalization for heart failure in patients treated with eplerenone, a mineralocorticoid receptor antagonist in the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) [19], is strikingly similar to that of empagliflozin (Figure 3).”
ResultManja, V., Albashir, S. M., & Guyatt, G. H. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.12.001 · Cited by 54
Neurohormonal Blockade in Heart Failure
von Lueder, T. G., Kotecha, D., Atar, D., & Hopper, I. (2017) · Cardiac failure review · doi:10.15420/cfr.2016:22:2 · Cited by 53
Harvey, A., Montezano, A. C. I., Hood, K. Y., Alves-Lopes, R., Rios, F. J. O., Ceravolo, G. S., Graham, D., & Touyz, R. M. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.05.002 · Cited by 53
Upadhya, B., Hundley, W. G., Brubaker, P. H., Morgan, T. M., Stewart, K. P., & Kitzman, D. W. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14940 · Cited by 55
“It is uncertain why aldosterone antagonism has not improved exercise capacity in most studies of HFpEF, but aldosterone antagonists may not substantially improve symptoms in individuals with HFrEF, despite their ability to increase survival and decrease HF hospitalizations.(29,42) As occurred in ALDO-DHF, significant…”
BackgroundThe Mechanism of Action of LCZ696
Menéndez, J. L. T. (2016) · Cardiac failure review · doi:10.15420/cfr.2016:1:1 · Cited by 55
“Neurohumoral activation, in particular, of the renin-angiotensinaldosterone system (RAAS) and the sympathetic nervous system, plays a major role in the development and progression of HF.1,2 The RAAS is an essential component in the regulation of cardiovascular homeostasis that exerts its actions through the hormones a…”
BackgroundInfluentialCommunity Care in England: Reducing Socioeconomic Inequalities in Heart Failure
Hawkins, N. M., Scholes, S., Bajekal, M., Love, H., O'Flaherty, M., Raine, R., & Capewell, S. (2012) · Circulation · doi:10.1161/circulationaha.111.088047 · Cited by 52
The multifaceted mineralocorticoid receptor
Gomez‐Sanchez, E., & Gomez‐Sanchez, C. E. (2014) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2014.tb00569.x · Cited by 55
“The addition of MR antagonists to standard treatment of heart and renal failure not only decreases morbidity and mortality, it has been shown in many studies to increase quality of life measures (386,431,502,509).”
Wiggins, B. S., Rodgers, J. E., DiDomenico, R. J., Cook, A. M., & Page, R. L., II (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1231 · Cited by 52
Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure
Nappi, J. M., & Sieg (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s13779 · Cited by 52
Muzzarelli, S., Maeder, M. T., Toggweiler, S., Rickli, H., Nietlispach, F., Julius, B. K., Burkard, T., Pfisterer, M. E., & Rocca, H. B. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.10.027 · Cited by 54
Inflammation and Fibrosis in Perirenal Adipose Tissue of Patients With Aldosterone-Producing Adenoma
Wu, C., Zhang, H., Zhang, J., Xie, C., Fan, C., Zhang, H., Wu, P., Wei, Q., Tan, W., Xu, L., et al. (2017) · Endocrinology · doi:10.1210/en.2017-00651 · Cited by 51
Kato, M., Furuie, H., Shimizu, T., Miyazaki, A., Kobayashi, F., & Ishizuka, H. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13616 · Cited by 52
Srivastava, P. K., Claggett, B. L., Solomon, S. D., McMurray, J. J. V., Packer, M., Zile, M. R., Desai, A. S., Rouleau, J. L., Swedberg, K. B., & Fonarow, G. C. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.3957 · Cited by 53
Self-citationKhames, A. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11010040 · Cited by 54
“EPL also helps to reduce the acute myocardial infarction death rate in patients with systolic dysfunction of the left ventricle and heart failure [10,11].”
BackgroundLenzini, L., Zanotti, G., Bonchio, M., & Rossi, G. P. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105332 · Cited by 53
Barrera‐Chimal, J., Kolkhof, P., Lima‐Posada, I., Alexandre, J., Rossignol, P., & Jaisser, F. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.2002844 · Cited by 54
Pharmacologic management of myxomatous mitral valve disease in dogs
Atkins, C. E., & Häggström, J. U. (2012) · Journal of Veterinary Cardiology · doi:10.1016/j.jvc.2012.02.002 · Cited by 55
Meredith, E. L., Ksander, G. M., Monovich, L. G., Papillon, J. P. N., Liu, Q., Miranda, K., Morris, P., Rao, C., Burgis, R., Capparelli, M. P., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400324c · Cited by 51
Li, C., Zhang, Y. Y., Frieler, R. A., Xiao, Z., Zhang, W. C., Sun, X., Yang, Q. Z., Min, S., Huang, B., Berger, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110950 · Cited by 51
Fool’s gold, lost treasures, and the randomized clinical trial
Stewart, D. J., & Kurzrock, R. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-193 · Cited by 51
The neuronal mineralocorticoid receptor: From cell survival to neurogenesis
Menuet, D. L., & Lombès, M. (2014) · Steroids · doi:10.1016/j.steroids.2014.05.018 · Cited by 55
Chernin, G., Gal‐Oz, A., Ben–Assa, E., Schwartz, I. F., Weinstein, T., Schwartz, D., & Silverberg, D. S. (2011) · Clinical Cardiology · doi:10.1002/clc.20987 · Cited by 51
New medical therapies for heart failure
von Lueder, T. G., & Krum, H. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.137 · Cited by 51
Self-citationBrownell, N. K., Ziaeian, B., & Fonarow, G. C. (2021) · Cardiac failure review · doi:10.15420/cfr.2021.18 · Cited by 54
Lullo, L. D., Lavalle, C., Scatena, A., Mariani, M. V., Ronco, C., & Bellasi, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123992 · Cited by 49
“At the same time, in the EMPHASISHF trial, adding eplerenone on top of medical therapy resulted in a statistically significant reduction in the risk of death and hospitalization (HR 0.63, 95% CI 0.54–0.74) in patients with chronic HFrEF [66].”
BackgroundInfluentialUdelson, J. E., & Konstam, M. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.01.009 · Cited by 50
Miller, A. L., Dib, C., Li, L., Chen, A. Y., Amsterdam, E. A., Funk, M., Saucedo, J. F., & Wang, T. Y. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.965012 · Cited by 51
Rassi, A. N., Cavender, M. A., Fonarow, G. C., Cannon, C. P., Hernandez, A. F., Peterson, E. D., Peacock, W. F., Laskey, W. K., Rosas, S. E., Zhao, X., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1019 · Cited by 50
BORER, J. S., Böhm, M., Ford, I., Robertson, M., Michel Komajda, N., Tavazzi, L., & Swedberg, K. B. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.10.033 · Cited by 51
Self-citationMineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives
Vizzardi, E., Regazzoni, V., Caretta, G., Gavazzoni, M., Sciatti, E., Bonadei, I., Trichaki, E., Raddino, R., & Metra, M. (2014) · IJC Heart & Vessels · doi:10.1016/j.ijchv.2014.03.005 · Cited by 50
“A number of large randomized controlled trials (RCTs) investigating the benefit of aldosterone antagonists in patients with systolic heart failure have demonstrated a clear reduction in death and cardiovascular morbidity [19,22,32], as well as benefits in systolic and diastolic patterns (Table 1).”
BackgroundInfluentialStructural determinants of ligand binding to the mineralocorticoid receptor
Huyet, J., Pinon, G. M., Fay, M., Rafestin-Oblin, M. E., & Fagart, J. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.035 · Cited by 57
Shen, Z., Chen, X.-Q., Sun, X., Sun, J., Zhang, W., Zheng, X., Zhang, Y.-Y., Shi, H., Zhang, J., Li, C., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.739243 · Cited by 50
“MR antagonists (spironolactone and eplerenone) are highly effective in treating heart failure (9-11).”
BackgroundSelf-citationImpact of Eplerenone on Cardiovascular Outcomes in Heart Failure Patients with Hypokalaemia
Rossignol, P., Girerd, N., Bakris, G. L., Vardeny, O., Claggett, B. L., McMurray, J. J. V., Swedberg, K. B., Krum, H., van Veldhuisen, D. J., Shi, H. H., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.688 · Cited by 50
Self-citationCombination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges
Lajoie, A., Bonnet, S., & Provencher, S. (2017) · Pulmonary Circulation · doi:10.1177/2045893217710639 · Cited by 51
Börschel, C. S., & Schnabel, R. B. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.11.123 · Cited by 52
Kobayashi, A., Azuma, K., Ikeda, K., & Inoue, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186683 · Cited by 49
Rush, C. J., Campbell, R. T., Jhund, P. S., Petrie, M. C., & McMurray, J. J. V. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy407 · Cited by 52
Self-citationOxidative Stress and Its Biomarkers in Cardiovascular Diseases
Valaitienė, J., & Laučytė-Cibulskienė, A. (2024) · Artery Research · doi:10.1007/s44200-024-00062-8 · Cited by 64
“For more than 10 years, eplerenone treatment was associated with a reduction in deaths from CVD or hospitalization for heart failure [128].”
Ca2+ Fluxes Involvement in Gene Expression During Cardiac Hypertrophy
Gomez, A. M., Ruiz‐Hurtado, G., Bénitah, J., & Domínguez‐Rodríguez, A. (2013) · Current Vascular Pharmacology · doi:10.2174/1570161111311040013 · Cited by 49
Eplerenone Is Not Superior to Older and Less Expensive Aldosterone Antagonists
Chatterjee, S., Moeller, C., Shah, N., Bolorunduro, O. B., Lichstein, E., Moskovits, N., & Mukherjee, D. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.12.018 · Cited by 49
Martin, R. E., Aebi, J. D., Hornsperger, B., Krebs, H.-J., Kuhn, B., Kuglstatter, A., Alker, A., Märki, H. P., Müller, S. G., Burger, D., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00851 · Cited by 50
Metadata
- Authors
- Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B.
- Affiliations
- Inserm (FR)
- Monash University (AU)
- University of Gothenburg (SE)
- Pfizer (United States) (US)
- London School of Hygiene & Tropical Medicine (GB)
- University of Michigan (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-06
- Volume
- 364
- Issue
- 1
- Pages
- 11-21
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2164705414
- Cited by
- 3,111
- References
- 27
- Citations by year
- 2026: 184 · 2025: 168 · 2024: 167 · 2023: 177 · 2022: 228 · 2021: 197 · 2020: 190 · 2019: 181 · 2018: 178 · 2017: 177 · 2016: 187 · 2015: 227 · 2014: 209 · 2013: 239 · 2012: 216
- FWCI
- 139.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- eplerenone, mineralocorticoid receptor antagonists, heart failure with reduced ejection fraction, mild symptoms, heart failure hospitalization, cardiovascular mortality, hyperkalemia, ejection fraction
- MeSH terms
- Eplerenone, Aged, Mineralocorticoid Receptor Antagonists, Cardiovascular Agents, Cardiovascular Diseases, Combined Modality Therapy, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Spironolactone, Proportional Hazards Models, Defibrillators, Implantable, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
